Duloxetine + Placebo

ApprovedCompleted
0 watching 0 views this week๐Ÿ”ฅ Hot
85
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Binge Eating

Conditions

Binge Eating, Depression

Trial Timeline

Oct 1, 2006 โ†’ Oct 1, 2009

About Duloxetine + Placebo

Duloxetine + Placebo is a approved stage product being developed by Eli Lilly for Binge Eating. The current trial status is completed. This product is registered under clinical trial identifier NCT00607789. Target conditions include Binge Eating, Depression.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (20)

NCT IDPhaseStatus
NCT01931475Phase 3Completed
NCT01451606ApprovedTerminated
NCT01226511Phase 3Completed
NCT01179672Phase 3Completed
NCT01237587Phase 3Completed
NCT01118780ApprovedCompleted
NCT01070329ApprovedCompleted
NCT01000805ApprovedCompleted
NCT01018680Phase 3Completed
NCT00965081ApprovedCompleted
NCT00803361Phase 3Completed
NCT00767806Phase 3Completed
NCT00433290Phase 3Completed
NCT00424593Phase 3Completed
NCT00457730Phase 2/3Completed
NCT00408876Phase 3Completed
NCT00408421Phase 3Completed
NCT00607789ApprovedCompleted
NCT00375973Phase 2/3Completed
NCT00233025Phase 3Completed

Competing Products

11 competing products in Binge Eating

See all competitors
ProductCompanyStageHype Score
Zonegran + sugar pillEisaiPhase 3
77
Dasotraline + PlaceboSumitomo PharmaPhase 2/3
65
dasotraline 4mg + dasotraline 6mg + PlaceboSumitomo PharmaPhase 3
77
DasotralineSumitomo PharmaPhase 3
77
Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml + PlaceboNovo NordiskPhase 3
76
Solriamfetol + PlaceboJazz PharmaceuticalsApproved
82
Sodium OxybateJazz PharmaceuticalsPhase 2/3
62
Solriamfetol 75mg, 150 mg, or 300 mgAxsome TherapeuticsPhase 3
74
Solriamfetol 150 mg + Solriamfetol 300 mg + PlaceboAxsome TherapeuticsPhase 3
74
RDC-0313 (ALKS 33) + PlaceboAlkermesPhase 2
49
ACT-539313 + PlaceboIdorsiaPhase 2
47